Edelman Joseph's Form 4 filing
Lyra Therapeutics, Inc. (LYRA) · filed Jun 2, 2023
- Accession no.
- 0001062993-23-012744
- Filed
- Jun 2, 2023, 4:11 PM ET
- Trade date
- May 31, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $9.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Edelman JosephCIK 0001164426 | Director, 10% Owner |
| Perceptive Advisors LLCCIK 0001224962 | Director, 10% Owner |
| Perceptive Life Sciences Master Fund LtdCIK 0001249675 | 10% Owner |
| Perceptive LS (A), LLCCIK 0001797811 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 31, 2023 | Common Stock | PPurchaseAcquired | +3,610,832 | $2.49F4 | +$8,999,998.76 | 11,469,117 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 31, 2023 | Common Stock | PPurchaseAcquired | +1,805,416 | –F4 | – | 1,805,416 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
These securities were acquired in units, with each unit consisting of one share of Common Stock and one Common Stock Purchase Warrant to purchase one share of Common Stock (the "Warrants"), at a combined purchase price of $2.4925 per unit. Each of the Warrants may not be exercised if the Reporting Persons and their affiliates would beneficially own more than 9.9% of the Issuer's outstanding shares of Common Stock following such exercise.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.